A Phase I Study of Premetrexed (Alimta) and Carboplatin and Radiation Therapy in Patients With Inoperable Non Small Cell Lung Cancer.
To determine the maximal tolerated dose (MTD) and toxicities of Pemetrexed (Alimta) when
administered concurrently with carboplatin and thoracic radiation therapy.
To determine, qualitatively, the occurrence of local tumor responses identified with this
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Response and Progression Free Survival
Maria Werner-Wasik, MD
Thomas Jefferson University
United States: Institutional Review Board
|Thomas Jefferson University Hospital||Philadelphia, Pennsylvania 19131|